Harry Glorikian and FDA’s Jennifer Dickey Headline 2014 Next Generation Dx Summit

Share Article

A plenary session featuring a “Regulatory Review of Clinical Sequencing Assays” with Harry Glorikian and Jennifer Dickey will bridge three days of presentations at the Sixth Annual Next Generation Dx Summit.

Cambridge Healthtech Institute’s 2014 Next Generation Dx Summit will bring together major players in clinical diagnostics for a plenary session, featuring a “Regulatory Review of Clinical Sequencing Assays” by Harry Glorikian and guest speaker Jennifer Dickey of the FDA Division of Immunology and Hematology Devices. The summit will be held August 19-21, 2014 at the Capital Hilton Hotel in Washington, DC. Moderated by Harry Glorikian, the presentation will bring together the 700+ participants of 10 focused diagnostics programs to address the FDA’s NGS validation process in light of the recent clearances provided for using sequencing in clinical decision making.

“The theme of this year’s event responds to the enormous potential for diagnostics resulting from new technologies and sequencing advancements, and the implication these advancements have on compliance, reimbursement and clinical outcomes,” states Christina Lingham, Conference Executive Director at Cambridge Healthtech Institute. “We’re thrilled to have industry mentor, Harry Glorikian, lead the discussion.”

Next Generation Dx Summit includes eleven courses and ten conference programs covering Point-of-Care Diagnostics; Predictive Cancer Biomarkers; Companion Diagnostics Strategy, Partnerships, Technologies and Reimbursement; Inherited Disease Diagnostics; NGS-Based Assays in the Clinical Setting; Molecular Diagnostics for Infectious Disease, Commercialization of Molecular Diagnostics, Clinical Application of Cell-Free DNA, and Single-Cell Sequencing. In addition to the regulatory plenary presentation, the event will feature a session on "Next-Generation Sequencing in Clinical Practice: Case Reports of Clinical Utility and Reimbursement," co-organized with the Association for Molecular Pathology (AMP). The session will be moderated by Dr. Elaine Lyon of ARUP and will include case presentations by Dr. Andrea Ferreira-Gonzalez of Virginia Commonwealth University, and Dr. Madhuri Hegde of Emory University School of Medicine.

Full program details can be found at http://www.nextgenerationdx.com. Early registration rates apply.

About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI) (http://www.chicorporate.com), founded in 1992, is the industry leader in providing superior-quality scientific information to eminent researchers and business experts from top pharmaceutical, biotech, and academic organizations. Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett Educational Services, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, and Cambridge Healthtech Media Group.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lisa Scimemi
Follow us on
Visit website